Nevertheless, despite the fact that the PGA was considered the reference in 39 studies involving other indices, it was used as the sole instrument in only 2 of them. In the second column, the definitions were reported according to the VAS used in the study. SLE is an immune-mediated multisystemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares [1, 2]. They participate in physiologic and inflammatory cascades and have become a major focus of research, yielding novel therapies for immune-mediated inflammatory diseases (IMID). , McGuire JL. MD globals may vary based on their age, gender, practice setting and experience (number of patients seen per year and years in practice). , Gladman DD.
Mayara Torres Silva de Oliveira, MD, MBA on LinkedIn: #medicinanuclear 2022 Jan 11;11(2):340. doi: 10.3390/jcm11020340. Federal government websites often end in .gov or .mil. Mok CC
, Patrick DL
et al. Thanou A
Assessing disease activity in rheumatic diseases such as systemic lupus erythematosus (SLE) is vital for effective treatment. Results. The sensitivity to change was estimated to be the smallest for the SLEDAI; the standardized response means were 0.48 when the physician global assessment was used as the standard and 0.01 when the patient global assessment was used . et al. , Sengupta M
, Mokkink LB
A good responsiveness for PGA was shown in eight studies. et al. The aim of this systematic literature review (SLR) is to describe and analyse the psychometric properties of PGA. However, it was used as a single outcome measure only in two studies [49, 100], while in the majority the PGA was scored together with another instrument (typically the SLEDAI) [2, 9, 11, 12, 21, 24, 30, 32, 34, 3740, 44, 45, 48, 49, 55, 58, 59, 61, 63, 64, 66, 67, 74, 75, 80, 82, 86, 8995, 103].
physician global assessment Latest Research Papers | ScienceGate Jiao H, Acar G, Robinson GA, Ciurtin C, Jury EC, Kalea AZ. Brunner HI
We analysed the performance of the SELENA SLEDAI Physician's Global Assessment (SSPGA) and the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) as measures . According to the authors, this difference was probably due to the greater familiarity of the physicians with the BILAG-2004 index. , Vogel-Claussen J
et al. PGA is a valid, responsive and feasible instrument, though its reliability was impacted by the scale adopted, suggesting the major need for standardization of its scoring. Piga M
Matthew Turk,1,2 Janet E Pope1,2 To cite: turk M, Pope Je. , Sjwall C. Strand V
The Handheld Dermatoscope as a Nail-Fold Capillaroscopic Instrument - JAMA .
Clinical Trial on Systemic Lupus Erythematosus (SLE): Blood sample (PGA) scoring of disease activity in systemic lupus erythematosus (SLE). may be asked to hyperventilate 3-4 min and watch a bright flashing light.
The Validity of Patient and Physician Global Disease Activity The Physician Global Assessment (PGA) is a visual analogue score that reflects the clinician's judgement of overall SLE disease activity. The https:// ensures that you are connecting to the This systematic literature review was conducted by two independent reviewers in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. physician's global assessment (PGA) of disease activity in SLE. , Bocci EB
Help us improve CareerBuilder by providing feedback about this job: Report this job Job ID: 2281236908. Results of a large, multicentric, nationwide study, American College of Rheumatology provisional criteria for global flares in childhood-onset systemic lupus erythematosus, A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus, Inactive disease and remission in childhood-onset systemic lupus erythematosus, Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus, Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual, Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. , Lau CS
The aim of this systematic literature review is to describe and analyse the . , Beresford MW
et al. Visual analogue scales (VAS) allow rapid, continuous scaling of disease severity. Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study. official website and that any information you provide is encrypted , Ogale S
, Mazur M. Fatemi A
Over the years, PGA-IGA scales were modified for the purpose of clinical settings and thus present a diversity in the number of response options (4 to 10 points), the response options label and the . , Siega-Riz AM
et al. , Bentow C
Whenever papers reported duplicate data, the most recent article was selected. The other authors have declared no conflicts of interest. All clinical diagnoses were verified by review of the patients' inpatient and outpatient files at the time of capillaroscopy. , Allen E
Physician Global Assessment (PGA) is a visual analogue score (VAS) that reflects the clinician's judgment of overall Systemic Lupus Erythematosus (SLE) disease activity.
Intoduction to X 20 - Physician Global Assessment For full access to this pdf, sign in to an existing account, or purchase an annual subscription. , Stavrakis S
~SLE~. Because of its dynamic nature, this disease has an unpredictable natural course leading to high . The last MEDLINE search was performed on 1 July 2019. Impact of anti-SARS-CoV-2 antibodies of different isotypes (IgA, IgG, IgM) on attainment of PGA . Methods Patients attending a rheumatology clinic between 2013 and 2017 completed specific (SLEQOL) and generic (SF36) health-related quality of life (HRQoL) surveys and rated . doi: 10.1136/rmdopen-2022-002395. , Anderson N
, Lin M
A prospective cohort study, Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients, A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index, Low disease activityirrespective of serologic status at baselineassociated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study, Definition and initial validation of a lupus low disease activity state (LLDAS), A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS), Prolonged remission in Caucasian patients with SLE: prevalence and outcomes, 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus, PRISMA Group. No study has evaluated the correlation of PGA with damage measures. RN-BSN HOLISTIC HEALTH ASSESSMENT ACROSS THE LIFESPAN (NURS 3315) Sociology of Social Problems (SOC213) The judgment of whether a patient with SLE has active disease is a central question both in routine patient management and in clinical research [4]. , Karp DR
A new tool -- the Lupus Activity Scoring Tool (LAST) - has been proposed to join the ranks of current disease activity indices. , Hochberg M. Wallace DJ
The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. Supervise the development of junior medical affairs staff . , Ding HH
, Hynan LS
Physician global assessment in systemic lupus erythematosus: Can we , Klein-Gitelman MS
et al. They proposed a physician global score on a 10cm visual analogue scale (VAS) to be used as a gold standard to compare six disease activity instruments [4]. Unauthorized use of these marks is strictly prohibited. Moreover, a difference between the interRR of the PGA assessed by an untrained physician (0.50.63) and a trained investigator (0.790.81) was found, suggesting the need for PGA scoring training or standardization [36]. An international panel of 79 SLE experts participated in a three-round Delphi consensus . Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus. , Perez-Gutthann S
1), accounting for 49 longitudinal cohort studies, 25 cross-sectional studies, 7 randomized controlled trials, 3 consensus conferences, 4 post-hoc analyses, 2 retrospective studies and 1 case series. , Petri MA
doi:10.1136/ rmdopen-2017-000578 Prepublication history and SLE3. Several definitions of minimum clinically important difference were retrieved: in the SRI-4, a significant worsening was defined as an increase of >10% on the PGA-VAS [111], corresponding to 0.3 points from baseline; Touma et al. The 4-point PGA (0, no flare; 1, mild; 2, moderate; 3, severe) showed the lowest IRR in assessing flare (ICC=0.18) compared with the BILAG-2004 (ICC=0.54) and SFI (ICC=0.21) [65]. Published by Oxford University Press on behalf of the British Society for Rheumatology. Forbess LJ
, Chizzolini C
The PGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. The literature search identified 93 articles, and 12 additional articles were retrieved from the reference list of those publications. Twenty-nine studies [25, 31, 3439, 41, 43, 48, 49, 5355, 59, 6164, 74, 75, 81, 82, 86, 92, 93, 96, 97] have assessed criterion validity of the PGA (Table2).
04 Measuring SLE disease activity in 2020: perspectives from clinical An international panel of 79 SLE experts participated in a three-round Delphi consensus process, in which 41 statements related to the PGA in SLE were . In one open-label study [43], the decrease in PGA score was considered the primary endpoint. Notorious to increase IOP and cause severe PAIN and headache; Diagnostics: - History - Tonometry examinations - measures IOP QUESTION A client states that the physician has told her that her intraocular was 14. However, no precise guidelines exist regarding the optimal use of the PGA in SLE, such as the adequate length of the VAS, the presence of anchored values, the incorporation of laboratory data and the time frame of assessment. Thanks to this feature, the PGA was included in composite indices with the aim of rating manifestations not included in glossary-based instruments such as the SLEDAI and BILAG [3] or for which a threshold has been defined (cytopenia). Thousand Oaks. , Hearth-Holmes M. Khan A
In only one study [4], was PGA sensitivity assessed comparing the change with an anchor [109], represented by the treatment sensitive index: PGA sensitivity was found to be between that of the BILAG (highest sensitivity) and the SLEDAI (lowest sensitivity). , Larson MG
Bethesda, MD 20894, Web Policies doi: 10.1136/lupus-2022-000700. , Emamikia S
Objective: The literature search identified 91 studies. , Skogh T
Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. The Physician's Global Assessment (PGA) is a pragmatic disease activity measure, using a 100 mm visual analogue scale (VAS) for physicians to quantify the patient's overall disease . It operates in Albuquerque, and New Mexico. sharing sensitive information, make sure youre on a federal National Library of Medicine A good responsiveness for PGA was shown in eight studies. Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. The PGA was developed on a 0 to 3 scale as part of the Lupus Activity Index. Definition: At least a 20%, 40%, 50%, or 70% improvement and an absolute improvement of at least 1 unit on a scale of 1-10 in at least three of the following criteria: patient global assessment; pain; function (BASFI); and. Of note, it is not trivial that we found a good convergent validity with other instruments (SLEDAI, BILAG, LAI, SLAM and ECLAM) [10, 23, 24, 26, 28, 29, 35, 54, 68, 76, 84, 99].
PDF Physician Global Assessment International Standardisation COnsensus in [8] and adopted in childhood SLE; the most common tool (the 03 VAS) was developed [68] to capture the concept of flare and is measured on a 3cm VAS in the SRI [3] and a 10cm VAS in the SFI [10, 104], but other scores (02, 04, 05, 07) [11, 53, 78, 80, 86, 87] and lengths (8cm, 15cm) [10, 8284] have also been used. , Petri MA
The pooled correlation coefficient (95% CI) is given both for the fixed effects model and the random effects model. Gladman DD
Vashisht P
, Gayet-Ageron A
Before , Kosinski M
Kiani AN
Thank you for submitting a comment on this article. et al.
Medizinische Universitt Graz Austria/sterreich - Forschungsportal Oxford Textbook of. The Physician Global Assessment (PGA) is a visual analogue score that reflects the clinician's judgement of overall SLE disease activity. Face validity is satisfied when the instrument is considered able to capture what it should capture (i.e. The assessment of disease activity in SLE is particularly challenging. , Gomez A
Petri M
Search for other works by this author on: Rheumatology Unit, AOU University Clinic and University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italy, Centre Hospitalier Universitaire de Dijon, Hpital Franois-Mitterrand, service de mdecine interne et maladies systmiques (mdecine interne, 2) et Centre dInvestigation Clinique, Service de rhumatologie, Hpitaux Universitaires de Strasbourg, Universit de Strasbourg, Centre National de Rfrence des Maladies Systmiques et Autoimmunes Rares Est Sud-Ouest (RESO). Beaton DE
Ragai Kiriakos, MD, MSc - Clinical Trials Physician - LinkedIn Ahmed S. - Managing Director/ Medical Lead - Global Bio-pharma . On stratifying the results by individual clinician, values ranged from 0.61 to 0.90, except for those reported by . Barr SG
et al. Touma Z
Face validity. Five studies have demonstrated good ICC values for reliability (all >0.60 and ranging up to 0.97). 2. , Sato JO
, Genovese M
An official website of the United States government.
Using the Physician Global Assessment in a clinical setting to - PubMed Construct validity is shown by the good correlation observed with the SLEDAI, BILAG, SLAM, LAI and ECLAM [10, 23, 24, 26, 28, 29, 35, 54, 68, 76, 84, 99]. Ward et al. In one study, the PGA was part of a modified score to assess disease activity in pregnancy (the SLE in Pregnancy Disease Activity Index) [51].
PDF Physician s global assessment is often useful in SLE, but not always , Shinada S
Epub 2014 Jul 10. et al. This week's edition of Faculty Publications includes Cedars-Sinai studies that were published Feb. 23-March 2. Montreal, Canada Area. government site. T1 - Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus. Myelogram - correct answer NPO for 4-6 hours.
Physician Global Assessment International - ScienceDirect et al. , Matos A
, Bresee C
Stojan G
, Holland M
et al. Construct validity is the degree to which the PGA relates to other instruments that measure the same concept [18]. Correlations with other instruments measuring similar constructs should typically demonstrate a coefficient (r) 0.50 [106]. Feasibility refers not to the quality of the outcome measure, but to aspects such as completion time, cost of an instrument, equipment and type and ease of administration. Moher D
BICLA is a validated composite global measure of SLE disease activity including SLEDAI-2K, CLASI-A, OCS dosage reduction, and patient-reported outcomes. RMD Open 2018;4:e000578. SELENA SLEDAI4. Feasibility is the ease of application of the instrument of measure in its intended setting [106]. Compared with nonresponders, BICLA responders had greater improvements in global and organ-specific disease activity (Physician's Global Assessment, SLE Disease Activity Index 2000, Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity, and joint counts; all nominal P < 0.001).
PDF Getting To Know Dr. Derek Shendell, New Safe Schools Project Director In our centre, new tools for the assessment of SLE activity: the Lupus Activity Scoring Tool (LAST) and Clinical Lupus Activity Scoring Tool (C-LAST) were developed and validated. AB - The Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus (PISCOS) study aimed to obtain an evidence . Int J Environ Res Public Health. Patient-Reported Outcomes in Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus (SLE) Treatment & Management - Medscape , Ho LY
Bookshelf A total of 91 articles were included in the study (Fig. To determine longitudinal associations between Physician Global Assessment (PGA) and patient-reported outcomes (PROs) in patients with systemic lupus erythematosus (SLE). , Magder LS
2014 - 20184 years. In 1988, Liang et al. et al.
Associations between physicians' global assessment of disease activity The PGA is a valid instrument but has variable reliability; its scoring should be standardized.
Systemic Lupus Erythematosus (SLE) | CDC , Merrill JT. Content validity pertains to the degree to which the instrument measures all facets of a construct of interest [20]: this property is satisfied if the PGA is considered able to measure all aspects of disease activity in SLE in a comprehensive way. , Ibaez D
, Gallacher AE
Physician global assessment in systemic lupus erythematosus: can we 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Navarra SV
History of Changes for Study: NCT05672576 2022 Sep 20;19(19):11895. doi: 10.3390/ijerph191911895. The .gov means its official. Feb 2016 - Jan 20182 years. , Andreoli L
Responsiveness, or sensitivity to change, is the usefulness of a test to detect minimum clinically important differences [20, 109]. The index assesses separately eight organ-based systems. , Hambleton IR
This may be explored through convergent and divergent validity. Content validity was reported in 89 studies. Disclosure statement: L.A. is a consultant for Alexion, Amgen, AstraZeneca, GlaxoSmithKline, Janssen-Cilag, LFB, Eli Lilly, Menarini France, Novartis, Pfizer, Roche-Chugai and UCB. All versions are validated and used by lupus researchers for clinical and research purposes. Supporting the face validity property, PGA was defined the gold standard in 11 studies [2, 10, 11, 21, 23, 49, 67, 76, 78, 84, 88] and in 32 it was used as the reference to which other activity scores were compared, such as the SLEDAI [4, 10, 13, 25, 27, 28, 31, 33, 35, 36, 41, 46, 47, 50, 51, 53, 62, 65, 68, 72, 73, 76, 81, 9699], BILAG [4, 27, 35, 36, 46, 65, 72, 73, 81, 98], SLAM [4, 72, 76, 99], LAI [68, 88], patient global assessment [81, 83, 84] and ECLAM [35]. HHS Vulnerability Disclosure, Help Responsiveness. PGA is a valid, responsive and feasible instrument, while its reliability was impacted by the scale adopted, suggesting the major need for a standardization of its scoring.
Visual Analog Scale Assessments Can Reliably Assess Disease Severity in SLE However, it is important to remember that not all clinical problems reported by a lupus patient are due to the disease. , Tanangunan R
Use of Physician Global Assessment in systemic lupus - PubMed In 89 studies [2, 3, 913, 21102] the PGA was used to measure disease activity as a whole, therefore satisfying the content validity criteria.
Treatment of lupus nephritis: consensus, evidence and perspectives The responsiveness of the PGA was assessed through different methods [109, 113] showing a high sensitivity for detecting clinical variations [84]. , Morabito LM
Background Physician Global Assessment (PGA) is a visual analogue score (VAS) that reflects the clinician's judgment of overall Systemic Lupus Erythematosus (SLE) disease activity. , Jolly M. Mazur-Nicorici L
, Klein-Gitelman MS
Parodis I
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Instrument selection using the OMERACT filter 2.1: the OMERACT methodology, The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes, Health measurement scales: a practical guide to their development and use, A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus, Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus, Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients, Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort, Comparison of the systemic lupus erythematosus activity questionnaire and the systemic lupus erythematosus disease activity index in a black Barbadian population, A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus, Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments, Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity, Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies, Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE, Validation of SIMPLE index for lupus disease activity, Performance characteristics of different anti-double-stranded DNA antibody assays in the monitoring of systemic lupus erythematosus, Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus, Therapeutic adherence in patients with systemic lupus erythematosus: a cross-sectional study, Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study, Comparison of the lupus foundation of America-rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical investigators or real-world clinicians, Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission, Impact of disease activity on health-related quality of life in systemic lupus erythematosusa cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS), Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study, Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus, Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings, Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned, Belimumab for the treatment of recalcitrant cutaneous lupus, Progression of noncalcified and calcified coronary plaque by CT angiography in SLE, Impact of heart rate variability, a marker for cardiac health, on lupus disease activity, The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index, Validation of the Lupus Impact Tracker in an Australian patient cohort, Axl, ferritin, IGFBP2 and TNFR2 as biomarkers in systemic lupus erythematosus, Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss, Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus, Predictors of pregnancy outcomes in patients with lupus: a cohort study, Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials, Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus, The Swiss Systemic lupus erythematosus Cohort Study (SSCS)cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland, How should lupus flares be measured?